@RaceOncology
1. Are there any accurate mouse models of carfilzomib?
2. According to the Q&A we would have expected carfilzomib to not show efficacy in this mouse model - so why use it to prove out synergy with Bisantrene? It seems to shed doubt on the accuracy of this model to simulate how MM will respond to drugs.
3. The anti-cancer synergy between Bis+Car seems limited after day 26, is this still clinically relevant? Are we just banking on the carfilzomib side of the combo being more efficacious in humans?4. As per the triangle report we know that we need not only cardio-protection, but anticancer synergy to produce a combo that insurers will pay for. If we don't see a higher degree of anti-cancer synergy, would insurers still pay because it's a reformulation of carfilzomib?
- Forums
- ASX - By Stock
- Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
@RaceOncology1. Are there any accurate mouse models of...
-
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.46 |
Change
0.055(3.91%) |
Mkt cap ! $239.3M |
Open | High | Low | Value | Volume |
$1.45 | $1.46 | $1.45 | $232 | 160 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 313 | $1.43 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.45 | 2896 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 313 | 1.425 |
1 | 491 | 1.420 |
1 | 235 | 1.415 |
5 | 13751 | 1.405 |
7 | 21645 | 1.400 |
Price($) | Vol. | No. |
---|---|---|
1.445 | 2896 | 2 |
1.450 | 341 | 1 |
1.455 | 660 | 1 |
1.460 | 754 | 1 |
1.475 | 755 | 1 |
Last trade - 10.15am 07/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |